article thumbnail

Eyelid Eczema (Eyelid Dermatitis) Prevention & Treatment Options

West Lake Dermatology

Eyelid eczema, also known as eyelid dermatitis, is a skin condition that affects the delicate skin around the eyes. Understanding the causes, symptoms, and treatment options can help those affected manage this condition effectively. What is Eyelid Eczema (Eyelid Dermatitis)? What is Eyelid Eczema (Eyelid Dermatitis)?

Eczema 36
article thumbnail

Switching from Dupilumab to Lebrikizumab in AD: What Does the Data Tell Us?

The Dermatology Digest

Linda Stein Gold, MD, Director of Dermatology Clinical Research at Henry Ford Health System in Detroit, MI, reviews new data on atopic dermatitis (AD) patients who switched to lebrikizumab (Ebyglyss, Lilly) from dupilumab (Dupixent, Sanofi and Regeneron) that was presented at the 2024 Fall Clinical Dermatology Conference in Las Vegas, NV. “If

article thumbnail

Unraveling the Advancements in Seborrheic Dermatitis Treatment

Dermatology Times

Raj Chovatiya, MD, PhD, takes a deep dive in the challenges, solutions, and further research needed to treat seborrheic dermatitis.

article thumbnail

Recognizing Atopic Dermatitis Heterogeneity and Tailoring Treatment

Dermatology Times

The panelist discusses how understanding the diverse manifestations of atopic dermatitis enables health care providers to develop personalized treatment approaches for optimal patient outcomes.

article thumbnail

Understanding Drug Interactions in Systemic Treatment: Impact on Atopic Dermatitis Symptoms

Dermatology Times

Dr Alexandra Golant discusses managing multiple conditions in a 17-year-old African American waitress, highlighting the complexities of treating moderate-to-severe atopic dermatitis alongside severe acne and oral contraceptives. She also addresses potential drug interactions, focusing on the safety of dupilumab in systemic treatment.

article thumbnail

Enhancing Atopic Dermatitis Treatment: Insights From Cutting-Edge Studies and Clinical Perspectives Part 1

Dermatology Times

A 5-expert panel delves into atopic dermatitis guidelines and recommendations and recent studies to make note of.

article thumbnail

Dupilumab for Atopic Dermatitis: 7 Years Later

Dermatology Times

Today officially marks 7 years since the US FDA approved dupilumab for the treatment of atopic dermatitis. Here's a look back at its approval timeline and all it has accomplished in the dermatology world in the time since.